首页> 外文OA文献 >Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors

【2h】

Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors

机译：鉴定浆液癌癌和良性浆膜卵巢肿瘤的新型候选血浆代谢产物生物标志物

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

AI期刊论文写作 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Matthew F. Buas; Haiwei Gu; Danijel Djukovic; Jiangjiang Zhu; Charles W. Drescher; Nicole Urban; Daniel Raftery; Christopher I. Li;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors [J] . Buas Matthew F., Gu Haiwei, Djukovic Danijel, Gynecologic Oncology: An International Journal . 2016,第1期

机译：鉴定用于区分浆液性卵巢癌和良性浆液性卵巢肿瘤的新型候选血浆代谢物生物标志物
2. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors [J] . Alon D Altman, Gregg S Nelson, Prafull Ghatage, Modern Pathology . 2013,第9期

机译：TP53和CDKN2A在区分卵巢高级浆液性癌和低度浆液性卵巢肿瘤中的诊断作用
3. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: Report of a series of cases of an unusual phenomenon [J] . BoydC., McCluggageW.G. American Journal of Surgical Pathology . 2012,第3期

机译：与高级别浆液性癌或未分化癌相关的低度卵巢浆液性肿瘤（低度浆液性癌和浆液性交界性肿瘤）：一系列异常现象的报告
4. Identification of Candidate Biomarkers from Integrated Proteomic Analysis of Human Cancer Cells and Plasma from an Ovarian Cancer Mouse Model [C] . Sharon J. Pitteri, Lellean JeBailey, Vitor M. Faca, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：从卵巢癌小鼠模型中鉴定人癌细胞和血浆综合蛋白质组学分析的候选生物标志物
5. Evaluation of Autoantibodies to Paraneoplastic Antigens as Early Detection Biomarkers for High-Grade Serous Ovarian Cancer [D] . Hurley, Laura Catherine. 2020

机译：对偏生剂抗原的自身抗体评价为早期检测生物标志物，高级浆液癌
6. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors [O] . Matthew F. Buas, Haiwei Gu, Danijel Djukovic, -1

机译：鉴定用于区分浆液性卵巢癌和良性浆液性卵巢肿瘤的新型候选血浆代谢物生物标志物
7. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors [O] . Alon D Altman, Gregg S Nelson, Prafull Ghatage, 2013

机译：TP53和CDKN2a与低级浆液肿瘤区分卵巢高级浆液癌的诊断效用
8. Pathogenesis of Ovarian Serous Carcinoma as the Basis for Immunologic Directed Diagnosis and Treatment. Project 1 - Molecular Characterization of Ovarian Serous Tumors Developing Along Different Pathways [R] . Kurman, R. J. , Shih, I. 2003

机译：卵巢浆液性癌的发病机制是免疫定向诊断和治疗的基础。项目1 - 沿不同途径发展的卵巢浆液性肿瘤的分子特征

Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors

著录项

引文网络

相似文献

相关主题

期刊订阅